Ghetti, G., Porta, C., & Povero, M. (2025). Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy. Farmeconomia. Health Economics and Therapeutic Pathways, 26(1). https://doi.org/10.7175/fe.v26i1.1574